{"id":668264,"date":"2023-09-18T11:00:01","date_gmt":"2023-09-18T11:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=668264"},"modified":"2023-09-18T11:00:01","modified_gmt":"2023-09-18T11:00:01","slug":"alzheimers-disease-pipeline-drugs-key-companies-insight-report-2023-companies-eisai-bioarctic-ab-biogen-hoffmannla-roche-cortexyme","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-pipeline-drugs-key-companies-insight-report-2023-companies-eisai-bioarctic-ab-biogen-hoffmannla-roche-cortexyme_668264.html","title":{"rendered":"Alzheimer\u2019s Disease Pipeline Drugs & Key Companies Insight Report 2023 | Companies: Eisai, BioArctic AB, Biogen, Hoffmann-La Roche, Cortexyme"},"content":{"rendered":"
\n
\"Alzheimer’s<\/a><\/div>\n
\n
Alzheimer\u2019s Disease Pipeline Insight Report 2023<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cAlzheimer\u2019s Disease (AD) \u2013 Pipeline Insights, 2023,\u201d report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer\u2019s Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n

DelveInsight’s “Alzheimer’s Disease Pipeline Insight 2023<\/a>” <\/strong>report provides comprehensive insights about key companies and pipeline drugs in the Alzheimer’s Disease pipeline landscapes. <\/p>\n

The report comprises Alzheimer’s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Alzheimer’s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Alzheimer’s Disease pipeline products.     <\/p>\n

Alzheimer’s Disease Overview<\/strong><\/p>\n

Alzheimer’s disease is a debilitating neurological disorder that gradually erodes memory and cognitive abilities, as well as the ability to perform even the most basic tasks. Alzheimer’s patients have difficulty doing simple tasks such as driving a car, preparing a meal, or paying bills. They can repeatedly ask the same questions, become easily disoriented, accidentally drop or misplace objects, and find even simple things perplexing. Some people become worried, frustrated, or aggressive as the disease progresses.<\/p>\n

Alzheimer’s disease is a disease whose precise causes are unknown. However, at a fundamental stage, brain proteins malfunction, disrupting the work of brain cells (neurons) and triggering a cascade of toxic events. Neurons become weakened, lose their ties, and ultimately die.<\/p>\n

Some of the key takeaways from the Alzheimer’s Disease Pipeline Report<\/a>:<\/strong><\/p>\n